Amarin reported $65.94M in Gross Profit on Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Alnylam Pharmaceuticals ALNY:US USD 223.19M 39.18M
Amarin AMRN:US USD 65.94M 7.31M
AstraZeneca AZN:LN USD 8.86B 3M
Biocryst Pharmaceuticals BCRX:US USD 72.21M 6.93M
Esperion Therapeutics ESPR:US USD 12.47M 2.81M
GlaxoSmithKline GSK:LN GBP 5.44B 650M
Halozyme Therapeutics HALO:US USD 161.66M 43.24M
Intercept Pharmaceuticals ICPT:US USD 77.16M 5.72M
IONIS PHARMACEUT IONS:US USD 158.25M 29.21M
JAZZ PHA JAZZ:US USD 806.99M 1.68M
Nektar Therapeutics NKTR:US USD 18.65M 2.18M
Neurocrine Biosciences NBIX:US USD 381.8M 8.4M
Novartis NOVN:VX USD 9.18B 151M
Teva Pharmaceutical Industries TEVA:US USD 1.71B 118M